Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]
News [5284]
Articles [130]
Editorials [4]
Conferences [158]
elearning [13]
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced...
Dr Mary McCormack - University College Hospital, London, UK
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )
23 Oct 2023
Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS...
Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy
Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer  ( Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy )
23 Oct 2023
Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer
Dr Aditya Bardia - Mass General Cancer Center, Boston, USA
Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )
23 Oct 2023
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced...
Prof Thomas Powles - Barts Cancer Centre, London, UK
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer ( Prof Thomas Powles - Barts Cancer Centre, London, UK )
22 Oct 2023
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
22 Oct 2023
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC
Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )
22 Oct 2023
A biomarker led approach to bladder cancer
Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...
A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )
22 Oct 2023
Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC
Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA
Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )
21 Oct 2023
Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant...
Dr Julien Hadoux - Institut Gustave Roussy, Villejuif, France
Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer ( Dr Julien Hadoux - Institut Gustave Roussy, Villejuif, France )
21 Oct 2023
Cost-benefit analysis of new cancer medicines: The difficult choices of...
Dr Nwamaka Lasebikan, Prof P.G. Roy, Dr Didier Verhoeven
Cost-benefit analysis of new cancer medicines: The difficult choices of governments ( Dr Nwamaka Lasebikan, Prof P.G. Roy, Dr Didier Verhoeven )
8 Oct 2023
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )
3 Oct 2023
Osimertinib plus chemotherapy shows superior results versus osimertinib alone...
Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA
Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer ( Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA )
21 Sep 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation